Suzanne Conzen, chief of the Hematology and Oncology Division at UT Southwestern Harold C. Simmons Comprehensive Cancer Center, appeared on the Cancer Luminaries podcast, a series launched by the UChicago Medicine Comprehensive Cancer Center to mark its 50th year as a National Cancer Institute-designated center.
Tobacco companies have capitalized on the Olympics’ widespread cultural impact since the birth of the modern Olympic Games in 1896—until the practice was stopped in 1987.
When air sirens sound over Kyiv, Ukraine, patients undergoing bone marrow transplants at Ohmatdyt National Children’s Hospital don’t have the option of going to the bomb shelter.
Two decades after uncovering the role of EGFR mutations in lung cancer, scientists are still grappling with lingering research questions.
In 1998, lung cancer was the leading cause of cancer deaths in the United States, with 160,000 deaths per year. That statistic inspired Matthew Meyerson, who would soon start working at the Dana-Farber Cancer Institute, to specialize in lung cancer.
Edward Sondik, an electrical engineer by training, followed a career path that led him to top public health positions.He was a director of the National Center for Health Statistics at CDC, an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control.
Edward Sondik, former director of the National Center for Health Statistics at CDC, who previously served as an acting director of NCI, and a deputy director of the NCI Division of Cancer Prevention and Control, died on June 25. He was 82.
Nathan Berger, professor of medicine, biochemistry, oncology, and genetics; the Hanna-Payne Professor of Experimental Medicine; the director of the Center for Science, Health, and Society; and a Distinguished University Professor at Case Western Reserve University, died on June 15. He was 83.
On Sept. 24, 2002, when I showed up at a meeting of the FDA Oncologic Drugs Advisory Committee, I had a pretty good idea that the drug on the agenda—AstraZeneca’s Iressa (gefitinib)—was having a surprising effect on some patients in third-line non-small cell lung cancer.
On Sept. 24, 2002, the Oncologic Drugs Advisory Committee recommended an accelerated approval for AstraZeneca’s Iressa (gefitinib). The recommendation concluded a meeting where ODAC weighed whether the drug, an EGFR tyrosine kinase inhibitor, could benefit patients with resistant or refractory non-small cell lung cancer as a third-line therapy.
